Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.

Trial Details

NCT ID
NCT04858880
Phase
NA
Sponsor
Lund University Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Locations (sample)
  • Jönköping, Sweden|57.78145,14.15618
  • Kalmar, Sweden|56.66157,16.36163
  • Lund, Sweden|55.70584,13.19321

Key Eligibility Criteria

  • Life expectancy \> 10 years
  • Age ≥18 years.
  • World Health Organization (WHO) performance status 0-1.
  • Estimated life expectancy \>10 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →